INTEGRA Biosciences has reported appreciable progress for over 10 years – averaging 18 p.c each year – and greater than doubling within the earlier two years. The corporate grew by 73 p.c in 2020, and has adopted this with a 46 p.c improve in turnover in 2021, reaching 191 million Swiss Francs.
The life sciences trade is prospering, and there’s at present unprecedented demand for liquid dealing with options. INTEGRA’s intensive portfolio of pipettes – together with the lately launched MINI 96, a 96 channel transportable digital pipette – is trusted by laboratories worldwide, serving to to drive the corporate’s continued enlargement. The corporate attracted an additional 1000 new prospects in 2021, and employed a further 100 staff to extend its international working capability. Comparable outcomes are anticipated in 2022, and the corporate is forecasting double-figure progress. That is prone to be pushed by a rise in direct gross sales in a number of nations throughout Asia and Europe, in addition to thrilling new product launches. Development of a brand new workplace and manufacturing constructing – the INTEGRA Campus – will proceed at Zizers, and one other 150 workers are deliberate to be employed throughout varied sectors globally.
Urs Hartmann, CEO at INTEGRA, commented: “Our modern options make for a dependable companion within the lab, and 99 p.c of our prospects say that they’d proceed to make use of, and advocate, INTEGRA merchandise. Making a constructive and secure working setting for our workers is essential to the corporate’s success, along with making certain that progress doesn’t compromise our long-term sustainability goals.”
Go to the INTEGRA Biosciences web site to be taught extra.
